Literature DB >> 6626743

Fibrin-associated plasminogen activation in alpha 2-plasmin inhibitor deficiency.

N Aoki, Y Sakata, A Ichinose.   

Abstract

The clot formed from the plasma of a patient with congenital deficiency of alpha 2-plasmin inhibitor underwent a spontaneous extensive fibrinolysis. Radiolabeled fibrinogen was added to the plasma before clotting, and the whole process of the fibrinolysis was followed by measuring the release of radiolabels. Plasminogen activation was also followed by measuring the amidolytic activity that developed. There was an initial latent period, followed by an exponential increase of fibrinolytic activity. During the latent period, there was little or no release of radiolabels and no development of amidolytic activity. During the latent period, the clot was washed thoroughly to remove unbound proteins from fibrin and was incubated in buffered saline. The washed clot still underwent fibrinolysis, similar to the original plasma clot, suggesting that the plasminogen/plasminogen activators bound to fibrin during the initial latent period are responsible for fibrinolysis. The amount of plasminogen bound to fibrin during the latent period was close to the amount of plasminogen activated during the whole process of fibrinolysis. When the amount of plasminogen bound to fibrin was decreased by epsilon aminocaproic acid, the extent of fibrinolysis was decreased in parallel with the decrease of the amount of the bound plasminogen. This suggests that the amount of plasminogen bound to fibrin is one of the determinants of the rate of the fibrinolytic process.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6626743

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator.

Authors:  I Y Sazonova; R A McNamee; A K Houng; S M King; L Hedstrom; G L Reed
Journal:  J Thromb Haemost       Date:  2009-06-30       Impact factor: 5.824

2.  Localization of the binding site of tissue-type plasminogen activator to fibrin.

Authors:  A Ichinose; K Takio; K Fujikawa
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

3.  Organization of the human alpha 2-plasmin inhibitor gene.

Authors:  S Hirosawa; Y Nakamura; O Miura; Y Sumi; N Aoki
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

4.  Synergistic fibrinolysis: combined effects of plasminogen activators and an antibody that inhibits alpha 2-antiplasmin.

Authors:  G L Reed; G R Matsueda; E Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

5.  Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.

Authors:  J Mimuro; S Kimura; N Aoki
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

Review 6.  Lessons from the aprotinin saga: current perspective on antifibrinolytic therapy in cardiac surgery.

Authors:  Masahiro Ide; Daniel Bolliger; Taro Taketomi; Kenichi A Tanaka
Journal:  J Anesth       Date:  2009-12-29       Impact factor: 2.078

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.